During the first quarter 2004 the Company sold 344,500 HQNT shares and realized a gain at time of sale of $519,524 due to the increase in the sale price from the cost basis of $.70 at time of acquisition.
During second quarter 2004 the Company received these 344,500 shares of common stock from an investor in exchange for 486,875 restricted common shares of H-Quotient, Inc. (HQNT). The 486,875 restricted common shares represents H-Quotient’s customer deposit for products to be delivered in future quarters.
During the second quarter 2004 the Company sold 358,869 HQNT shares and realized a loss at time of sale of $8,445 due to the decline in the FMV of the stock the from December 31, 2003 closing price of $.72. This represents a net realized gain of $511,079 for the first six months of 2004.
• During second quarter 2005 the Company recorded an unrealized loss in the amount of $32,454 which reflects the decline in the FMV of 301,506 HQNT shares from March 31, 2004 at $.45 to $.30 at June 30, 2005; a decline in the FMV of 10,741 HNSTshares from March 31, 2005 at $.075 to $.065 at June 30, 2005; an increase in the FMV of 71,951 SNDH shares of $.23 at June 6, 2005 to $.27 at June 30, 2005; and 400,000 HQNT shares from March 31, 2005 at $.275 to $.30 at June 30, 2005.
During the first quarter 2005 the Company recorded an unrealized loss in the amount of $30,741 which reflects the decline in the FMV of 301,506 HQNT shares from December 31, 2004 at $.55 to $.45 at March 31, 2005; and a decline in the FMV of 10,741 HNST shares from December 31, 2004 at $.13 to $.075 at March 31, 2005.
During the second quarter 2004 the Company recorded an unrealized loss in the amount of $214,317 which reflects the decline in the FMV of 301,431 HQNT shares from March 31, 2004 at $1.70 to $.989 at June 30, 2004. During the first quarter 2004 the Company recorded an unrealized gain in the amount of $295,402 which reflects the increase in the FMV of 301,431 HQNT shares from $.72 to $1.70 at March 31, 2004. This represents a net unrealized gain of $81,085 for the first six months of 2004.
Veridien Corp · 10QSB · For 6/30/5
secinfo.com
During first quarter 2004 the Company signed an agreement with H-Quotient, Inc. (HQNT) which involves the sale of product, licensing and service fees. We continue active promotion of our product line through trade-show presentations and direct calls on both existing and potential customers. Our goal is to continue to expand our product lines and we anticipate new products, which are scheduled with various releases this year, will generate new revenue in this and future years. In addition, we continue to pursue strategic alliances with other corporations that have existing distribution networks. Our goal for these alliances is to create immediate distribution and fulfillment avenues for our products, while focusing on our capital resources. We have recently begun expanding our revenue base to include not only sale of our proprietary products but also the sale of licensing rights relating to our existing and/or new technology, as well as service fees. We intend to continue to broaden this initiative from new technology created by Mycosol including their seven patents pending.
• During the first quarter 2004, the Company recorded an unrealized gain in the amount of $295,402 which reflects the increase in the FMV of 301,431 HQNT shares from $.72 to $1.70 at March 31, 2004.
During first quarter 2004, the Company sold 358,869 HQNT shares and realized a loss of $8,445 due to the decline in the FMV of the stock from December 31, 2003 at $.72.
• During first quarter 2005, the Company recorded an unrealized loss in the amount of $30,741 which reflects the decrease in the fair market value of 301,506 HQNT common shares from $.55 to $.45 and Healthnostics, Inc. (HNST) common shares from $.13 to $.075 at March 31, 2005.
Veridien Corp · 10QSB · For 3/31/5
secinfo.com |
